Streetwise Reports

All Posts

• Three Exciting Names in Regenerative Medicine

  By Streetwise Reports - May 1, 2013 | Tickers: CYTX, MSB, SGMO

  By George S. Mack of The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  I have been a critic of pharma’s absence from the stem cell industry. The major drug manufacturers have held on to the small-molecule business model for dear life, and now even after nearly 15 years of stagnation they still don’t seem more »

• A Prescription for a Healthy Retirement Plan from Stansberry’s Doc Eifrig

  By Streetwise Reports - April 24, 2013 | Tickers: CVX, XOM, OXY, RDS-B

  By Peter Byrne of The Energy Report

  What is the best way to juice up your portfolio for a rich retirement? Stansberry Research's resident medical doctor and retirement investment guru, David “Doc” Eifrig told The Energy Report that natural gas and uranium are here to stay and shared tips for maintaining financial and fiscal health for the golden years.

  Eifrig argued that cheap interest rates will generate more business more »

• Three Outside the Box Biotechs

  By Streetwise Reports - April 1, 2013 | Tickers: BDX, LGND, MNKD, ONXX, UNIS

  By George S. Mack of The Life Sciences Report

  I had a really nice chat with Griffin Securities analyst and scientific director Keith Markey about a wide-ranging group of topics. My goal is to always talk about individual biotech and sometimes medtech stocks, but we got started on another subject right away. Although he’s been an analyst for 25 years now, Markey started his career as a molecular biologist more »

• Five Exciting Biotech Stories

  By Streetwise Reports - March 6, 2013 | Tickers: ACAD, CERS, NVAX, THLD

  I had a chat with Senior Analyst and Managing Director George Zavoico of MLV & Co. He’s an interesting guy, and he’s worked in the industry at both big pharma and small biotech companies. His ideas are worth hearing and heeding, as he has twice received The Financial Times/Starmine Award for being among the top-ranked earnings estimators in biotech. Each time we talk, Zavoico presents an interesting list more »

• 5 Value and Growth Medtech Stories

  By Streetwise Reports - March 4, 2013 | Tickers: DXCM, GMED, PODD, NUVA

  The not-so-secret ingredient necessary for growth in medtech is innovation. Unless new prosthetics and instruments are differentiated from their predecessors, clinicians just won’t look at them because they are inherently resistant to change without an incentive. “The advantage of a new technology, a new product, a little better mousetrap or a lot better mousetrap, is you will drive higher pricing,” says Analyst and Managing Director William Plovanic of Canaccord more »

• Big Growth Stories in Biotech

  By Streetwise Reports - February 19, 2013 | Tickers: IRWD, SGYP, TSRX

  By George S. Mack of The Life Sciences Report.

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

   

  Bacteria are pure survivalists, and over billions of years they have evolved to produce ever-newer chemicals to protect themselves against other bugs, and in the last 100 years they have begun to protect themselves against the antibiotics that humans have developed from those more »

• Two Biotech Names Without the Microcap Roller Coaster

  By Streetwise Reports - February 1, 2013 | Tickers: ACAD, DEPO

  Investors familiar with Zacks Investment Research know that the company is small-cap focused and that it leans heavily toward companies that don’t get much coverage from Wall Street. The idea is to produce the kind of sophisticated research one might find in the more recognizable names that get aired on financial television and other media. Battered and forgotten names can be interesting for investors willing to take another look more »

• Five Amazing Biotech Picks with Futuristic Technology

  By Streetwise Reports - January 29, 2013 | Tickers: ARIA, ASTX, GALE, SRPT

  Michael King is looking for the monoclonal antibodies of tomorrow. When I first spoke to him 15 or more years ago, King was talking up Immunex, which would later be taken out by Amgen for $16 billion for its anti-tumor necrosis factor (anti-TNF) fusion protein Enbrel (etanercept) to treat rheumatoid arthritis. Today Amgen’s (via Immunex) Enbrel and the anti-TNF monoclonal antibodies that would follow-- Johnson & Johnson’s Remicade (infliximab more »

• Two Biotech Growth Stocks from a Resource Investor’s Perspective

  By Streetwise Reports - January 16, 2013 | Tickers: OPK

  By George S. Mack of The Life Sciences Report

   

  Michael Berry is known to investors as a small- and micro-cap natural resources expert and Discovery Investing publisher who understands the importance of good management and how it can make a bundle for growth seekers. Now, he’s turning some of his attention to the life sciences sector where he is also enjoying some successes. It was with a great deal more »

• Invest in the Great Progress of Hepatitis C

  By Streetwise Reports - December 8, 2012 | Tickers: ACHN, GILD, IDIX, JNJ

  By George S. Mack of The Life Sciences Report.

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  There are a lot of drug candidates in company pipelines for hepatitis C (HCV). In fact, your head could spin as you recite the product code number and letter combinations. I spoke with Sagient Research Analyst John Tucker who had just gotten back more »

• Personalized Diagnostic Medicine Coming of Age

  By Streetwise Reports - December 6, 2012 | Tickers: EXAS, GHDX, OPK

  By George S. Mack of The Life Sciences Report.

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  As little as a decade ago we were all thinking in terms of one blood draw being the be-all and end-all of diagnostics. With the first human genome sequenced, it would only require a panel of genetic, epigenetic, proteomic and small molecule metabolic more »

• Four Biotech Ideas With Legs to Run

  By Streetwise Reports - September 24, 2012 | Tickers: BCRX, RVXCF, SPPI, THLD

  By George S. Mack, The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  I had an opportunity to ask George Zavoico a few questions for The Life Sciences Report. Zavoico is senior biotechnology analyst at the boutique investment bank, MLV & Co. He originally got his career underway as a research scientist and worked in big pharma at more »

• Five Medtech Ideas to Leverage

  By Streetwise Reports - September 16, 2012 | Tickers: CSII, EXAC, HCSG, ICUI, VASC

  By George S. Mack, The Life Sciences Report

  Before spending the last decade as a sellside analyst, James Terwilliger now with The Benchmark Company worked at Johnson & Johnson and other medtech companies where he learned quickly that the way to a surgeon's heart is to bring shiny new technology into the office. Physicians who spend their working lives in interventional cath labs or hospital operating suites have a natural more »

• Four Important Biotech Stocks Targeting Unmet Needs

  By Streetwise Reports - September 1, 2012 | Tickers: ACOR, AMRN, NKTR, NBIX

  By George S. Mack, The Life Sciences Report

   

  Biotech rallies need catalysts to be sustained. Market moving events include drug approvals, such as a couple of obesity products from VIVUS Inc. and Arena Pharmaceuticals Inc., as well as a product to help control serum lipids from Amarin Corp. Plc (NASDAQ: AMRN). But the major diagnostic feature of a market that might be putting it all together is merger and acquisition more »

• Six Disruptive Biotech Stocks

  By Streetwise Reports - August 18, 2012 | Tickers: AVEO, DNDN, IMGN, SGEN, VRTX

  By George S. Mack, The Life Sciences Report

   For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

   

  Imagine a novel discovery or even a novel platform that just fizzles. To a technology freak like me that sounds so disappointing to think that you can actually discover breakthrough ideas that are not disruptive and don't really change much. I recently spoke more »

• Biotech Stocks Live (and Die) on the Calendar

  By Streetwise Reports - August 15, 2012 | Tickers: ACHN, ARNA, GILD, OREX, VVUS

  By George S. Mack, The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

   

  Since the beginning of the biotech revolution, analysts have kept spreadsheets, tables and calendars to catch the next whiff of data coming out of companies whose futures hang in the balance. I recently interviewed Vice President Michael Hay of Sagient Research Systems for The more »

• Exclusive: Five Biotechs Picks from a Top Biotechnology Analyst

  By Streetwise Reports - August 3, 2012 | Tickers: CELG, CLDX, IMGN, NLNK, ONTY

  Five biotechs to consider

  By George S. Mack, The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  Immunity is cancer's enemy

  The complexity of the mammalian immune system is daunting for molecular biologists and drug developers, but incremental progress has brought biotech and biopharma to the point where small molecules and biologics are being developed with more »

• Three Important Biotech Names

  By Streetwise Reports - July 16, 2012 | Tickers: ONCY, QLTI

  Three Important Biotech Names

  By George S. Mack, The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  Fascinating oncolytic viral therapy awaits important data.

  The term reovirus (respiratory enteric orphan virus) was originated by Albert Sabin whose name is now synonymous with the oral poliomyelitis vaccine that bears his name. Now after more than a half-century of more »

• Hidden Small Cap Medical Device Companies with Big Growth Potential

  By Streetwise Reports - July 2, 2012 | Tickers: CSII, CERS, COV, LLY, SPNC, UNIS

  Hidden Small Cap Medical Device Companies with Big Growth Potential

  By George S. Mack, The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com

  I've been involved in healthcare as a clinician, writer or analyst for four decades, and every now and then a public company will come to light that went previously unnoticed or unknown by more »

• Former Drug Developer Discovers Next-Generation Biotech Stocks

  By Streetwise Reports - June 22, 2012 | Tickers: ACHN, ACOR, AMRN, IDIX, MDVN

  Former Drug Developer Discovers Next-Generation Biotech Stocks

  By George S. Mack, The Life Sciences Report

  Management is the key ingredient

  Raghuram "Ram" Selvaraju, an analyst I recently interviewed for The Life Sciences Report, began his initial career in translational drug discovery at Serono in 2000 with early and remarkable success. As a young researcher he demonstrated real insight and ability when he discovered the first novel protein candidate ever developed more »

• Page 1 of 3
• »